206
L. Schönstein et al. / Tetrahedron: Asymmetry 24 (2013) 202–206
Avance DRX 400 spectrometer. Melting points were determined on
a Kofler apparatus.
dried on Na2SO4, filtered and evaporated. Both enantiomers were
obtained as white crystalline products: (S)-5 calycotomine
(23 mg, 76%), mp 139–140 °C, Ref. 24 mp 138 °C ½a D25
¼ ꢀ15 (c
ꢂ
4.2. Small-scale enzymatic reactions
0.18, CHCl3), Ref. 23 ½a D25
¼ ꢀ13:1 (c 0.38, CHCl3) ee = 99% [(deter-
ꢂ
mined after derivatization with Boc2O in the presence of DMAP/Py
The preliminary small-scale experiments were carried out in a
continuous-flow system. The racemic N-Boc-protected amino alco-
hol ( )-3 (0.012 M, 3.9 mg mLꢀ1) and vinyl acetate (0.024 M,
2.06 mg mLꢀ1) were dissolved in toluene (1 mL), and the solution
was then pumped through the heated and compressed enzyme-
charged cartridge at a flow rate of 0.1 mL minꢀ1. In order to follow
the progress of the reactions and to determine the ee values of the
products, HPLC with a chiral column was used. The ee values for
the unreacted amino alcohols (R)-3, (S)-2 and ( )-1 and the product
amino esters (R)-6 and ( )-7 were determined on a Chiralpak IA
column (4.6 ꢃ 250 mm); eluent: n-hexane/iPA (85:15); flow rate:
0.5 mL minꢀ1; detection at 260 nm; retention time (min) for (R)-
3: 25.9, for (S)-3: 18.7, for (R)-6: 16.8, for (S)-6: 18.4, for (S)-2:
35.1, for (R)-2: 24.1, for ( )-7: 15.2 and 20.8, and for ( )-1: 24.1
and 40.6. The ee value for the amino ester (S)-4 was determined
on a Chiralcel OD-H column (4.6 ꢃ 250 mm); eluent: n-hexane/
iPA (95:5); flow rate: 0.5 mL minꢀ1; detection at 260 nm; retention
time (min) for (R)-4: 30.1, and for (S)-4: 25.2.
(1:9)]; (R)-5 calycotomine (25 mg, 73%), mp 140–141 °C,
½
a 2D5
ꢂ
¼ þ16 (c 0.165, CHCl3), ee = 99%. 1H NMR (400 MHz, CDCl3)
data for (S)-5 were identical to those of (R)-5: d = 1.81–2.18 (br s,
2H, OH, NH), 2.68–2.73 (m, 2H, CH2–CH2–NH), 3.07–3.11 (m, 2H,
CH2–CH2–NH), 3.62–3.67 (m, 1H, CH–CH2–OH), 3.76–3.80 (dd,
J = 4.3 Hz, J = 4.3 Hz, 1H, CH–CHH–OH), 3.87 (s, 6H, 2 ꢃ CH3O–Ar),
3.98–4.00 (dd, J = 4.4 Hz, J = 4.2 Hz, 1H, CH–CHH–OH), 6.61 (s, 1H,
Ar), 6.62 (s, 1H, Ar) ppm. 13C NMR (400 MHz, CDCl3) data for (S)-
5 were identical to those of (R)-5: d = 29.5, 39.2, 56.2, 56.4, 64.5,
64.6, 109.6, 112.5, 127.6, 128.1, 147.9, 148.1 ppm. C12H17NO3
(223.27): Calcd C, 64.55; H, 7.67; N, 6.27. Found: C, 64.41; H,
7.52; N, 6.21.
Acknowledgments
We are grateful to the Hungarian Research Foundation (T
049407). Thanks are also due to TÁMOP-4.2.2/A-11/1/KONV-
2012-0052 for financial support.
4.3. Gram-scale resolution of ( )-3
References
1. (a) Herbert, R. B. In The Chemistry and Biology of Isoquinoline Alkaloids; Philips, J.
D., Roberts, M. F., Zenk, M. H., Eds.; Springer Verlag: Berlin, Heidelberg, New
York, Tokyo, 1985; p 231; (b) Chrzanowska, M.; Rozwadowska, M. D. Chem. Rev.
2004, 104, 3341–3370; (c) Miyazaki, M.; Ando, N.; Sugai, K.; Seito, Y.; Fukuoka,
H.; Kanemitsu, T.; Nagata, K.; Odanaka, Y.; Nakamura, K. T.; Itoh, T. J. Org. Chem.
2011, 76, 534–542.
2. Zhang, Q.; Tu, G.; Zhao, Y.; Cheng, T. Tetrahedron 2002, 58, 6795–6798.
3. Tóth, B. E.; Bodnár, I.; Homicskó, K. G.; Fülöp, F.; Fekete, M. I. K.; Nagy, G. M.
Neurotoxicol. Teratol. 2002, 24, 655–666.
Compound ( )-3 (500 mg, 1.55 mmol) was dissolved in toluene
(40 mL). CAL-B (1 g) and vinyl acetate (266.88 mg, 3.1 mmol) were
added and the mixture was shaken in an incubator shaker at 60 °C
for 1 h. The reaction was stopped at 50% conversion (eep = 99% and
ees = 99%) by filtering off the enzyme, and the solvent was evapo-
rated off. The products were separated by column chromatography
on silica, with elution with n-hexane/EtOAc (5:1), affording ester
4. Boyd, E. M.; Knight, L. M. J. Pharm. Pharmacol. 1964, 16, 118–124.
5. Al-Yahya, M. A.; Hassan, M. M. A. Anal. Profiles Drug Subst. 1982, 11, 407–461.
6. (a) Ortín, I.; González, J. F.; Cuesta, E.; Manguan-García, C.; Perona, R.;
(S)-4 {241 mg, 43%; ½a D25
¼ ꢀ103 (c 0.24, CHCl3) as a white crystal-
ꢂ
line product; mp 72–74 °C, ee = 99%} and amino alcohol (R)-3
{230 mg, 46%, ½a 2D5
¼ þ82 (c 0.255, CHCl3) as a light-yellow oil;
ꢂ
´
Avendano, C. Bioorg. Med. Chem. 2008, 16, 9065–9078; (b) Cuevas, C.;
Francesch, A. Nat. Prod. Rep. 2009, 26, 322–337; (c) Schwartsmann, G.;
Schwartsmann, G.; Brondani da Rocha, A.; Mattei, J.; Lopes, R. Expert Opin.
Investig. Drugs 2003, 12, 1367–1383.
ee = 99%}. 1H NMR (400 MHz, CDCl3) for (S)-4: d = 1.51 [s, 9H,
C(CH3)3], 2.04–2.15 (m, 3H, OCOCH3), 2.63–2.73 (m, 1H, Ar–CHH),
2.78–2.97 (m, 1H, Ar–CHH), 3.17–3.40 (m, 1H, CH2–CHH–NBoc),
3.88 (s, 6H, 2 ꢃ CH3O–Ar), 3.99–4.42 (m, 3H, CH2–OCOCH3, CH2–
CHH–NBoc), 5.21–5.46 (br s, 1H, CH–CH2–OCOCH3), 6.64 (s, 1H,
Ar), 6.72 (s, 1H, Ar) ppm. 13C NMR (400 MHz, CDCl3) for (S)-4:
d = 20.3, 27.5, 27.8, 38.0, 55.2, 55.4, 64.7, 79.2, 109.7, 111.1,
124.1, 126.7, 147.0, 147.7, 154.1, 169.9 ppm. C19H27NO6 (365.42):
Calcd C, 62.45; H, 7.45; N, 3.83. Found: C, 62.29; H, 7.41; N, 3.69.
1H NMR (400 MHz, CDCl3) for (R)-3: d = 1.53 [s, 9H, C(CH3)3],
2.67–2.75 (m, 1H, Ar–CHH), 2.80–2.91 (m, 1H, Ar–CHH), 3.31–
3.47 (br s, 1H, CH2–CHH–NBoc), 3.78–3.91 (m, 2H, CH2–OH over-
lapping with s, 6H, 2 ꢃ CH3O-Ar), 3.95–4.09 (m, 1H, CHH–NBoc),
5.10–5.27 (br s, 1H, CH–CH2–OH), 6.65 (s, 1H, Ar), 6.71 (s, 1H, Ar)
ppm. 13C NMR (400 MHz, CDCl3) for (R)-3: d = 28.5, 28.8, 40.0,
56.3, 56.4, 56.7, 62.0, 80.8, 110.7, 111.9, 125.8, 127.6, 148.0,
148.5, 154.0 ppm. C17H25NO5 (323.38): Calcd C, 63.14; H, 7.79; N,
4.33. Found: C, 63.26; H, 7.84; N, 4.21.
7. Taniyama, D.; Hasegawa, M.; Tomioka, T. Tetrahedron: Asymmetry 1999, 10,
221–223.
8. White, E. P. N.Z. J. Sci. Technol. 1944, 25B, 137–162.
9. Loy, G.; Cottiglia, F.; Garau, D.; Deidda, D.; Pompei, R.; Bonsignore, L. II Farmaco
2001, 56, 433–436.
10. Morimoto, T.; Suzuki, N.; Achiwa, K. Tetrahedron: Asymmetry 1998, 9, 183–187.
11. Paál, T. A.; Liljeblad, A.; Kanerva, L. T.; Forró, E.; Fülöp, F. Eur. J. Org. Chem. 2008,
5269–5276.
12. Wegner, J.; Ceylan, S.; Kirschning, A. Chem. Commun. 2011, 47, 4583–4592.
13. Wiles, C.; Watts, P. Green Chem. 2012, 14, 38–54.
14. Falus, P.; Boros, Z.; Hornyánszky, G.; Nagy, J.; Darvas, F.; Ürge, L.; Poppe, L.
Tetrahedron Lett. 2011, 52, 1310–1312.
15. Ötvös, S. B.; Mándity, I. M.; Fülöp, F. ChemSusChem 2012, 5, 266–269.
16. Tomin, A.; Hornyánszky, G.; Kupai, K.; Dorkó, Zs.; Ürge, L.; Darvas, F.; Poppe, L.
Process Biochem. 2010, 45, 859–865.
17. Forró, E.; Schönstein, L.; Fülöp, F. Tetrahedron: Asymmetry 2011, 22, 1255–1260.
18. (a) Lázár, L.; Fülöp, F.; Bernáth, G.; Mattinen, J. Org. Prep. Proc. Int. 1993, 25, 91–
97; (b) Fülöp, F.; Forró, E.; Martinek, T.; Günther, G.; Sillanpää, R. J. Mol. Struct.
2000, 554, 119–125; (c) Kóbor, J.; Fülöp, F.; Bernáth, G. Heterocycles 1986, 24,
2227–2231; (d) Zalán, Z.; Martinek, T. A.; Lázár, L.; Sillanpää, R.; Fülöp, F.
Tetrahedron 2006, 62, 2883–2891.
19. Sabbani, S.; Hedenström, E.; Andersson, J. Tetrahedron: Asymmetry 2007, 18,
1712–1720.
20. Csajági, C.; Szatzker, G.; Toke, E. R.; Ürge, L.; Darvas, F.; Poppe, L. Tetrahedron:
4.4. Preparation of (S)- and (R)-(6,7-dimethoxy-1,2,3,4-tetrahy-
droisoquinolin-1-yl)methanol (S)-5 and (R)-5
}
Asymmetry 2008, 19, 237–246.
21. Kanerva, L. T.; Sundholm, O. J. Chem. Soc., Perkin Trans. 1 1993, 2407–2410.
22. Li, X.-G.; Kanerva, L. T. Adv. Synth. Catal. 2006, 348, 197–205.
23. Pedrosa, R.; Andrés, C.; Iglesias, J. M. J. Org. Chem. 2001, 66, 243–250.
24. Kanemitsu, T.; Yamashita, Y.; Nagata, K.; Itoh, T. Synlett 2006, 1595–1597.
At first, (S)-4 (50 mg, 0.137 mmol) or (R)-3 (50 mg, 0.155 mmol)
was refluxed for 5 h in 18% HCl (10 mL). The solvent was then
evaporated off, and 5% NaOH was added until pH = 10. The residue
was extracted with CH2Cl2 (3 ꢃ 30 mL). The organic layer was